Status:
ACTIVE_NOT_RECRUITING
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Lead Sponsor:
Methodist Health System
Conditions:
Streptococcus Pneumoniae
Eligibility:
All Genders
18-75 years
Brief Summary
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective ...
Detailed Description
The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common...
Eligibility Criteria
Inclusion
- • ≥18 years of age
- S. pneumoniae isolated from ≥1 blood cultures
- Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
- Clinical stability by day 10 of therapy
Exclusion
- • Treatment duration \<5 days or \>16 days
- Death before completion of therapy (\<10 days vs. ≥ 10 days )
- Polymicrobial BSI
- Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)
Key Trial Info
Start Date :
June 23 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 23 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06096025
Start Date
June 23 2023
End Date
June 23 2026
Last Update
July 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203